Baba Ramdev's infertility medicine ad not misleading: Paswan

Image
IANS Kolkata
Last Updated : May 01 2015 | 8:42 PM IST

Even as the controversy over Baba Ramdev's infertility medicine rages on, union Food, Public Distribution and Consumer Protection Minister Ram Vilas Paswan said on Friday that its advertisement cannot be classified as "misleading" and assured that the matter was being probed.

"When people don't get the promised results as claimed by a product, then only it can be termed as misleading... This product cannot be classified under misleading advertisement," he told media persons here.

"The issue which is raging on in parliament is about when the government is promoting 'Beti Bachao, Beti Padhao' campaign, why is this medicine promoting only male child," he said.

According to Paswan, while allopathic medicines can be tested in laboratories and thereafter animal-testing can be done to analyse its "effects and after-effects", homeopathic and ayurvedic medicines cannot be done so.

"Promoting only a male child is illegal... The union home and heath ministers are already looking into it," he said.

The issue had caused an uproar in the Rajya Sabha on Thursday when members raising the issue of the product, 'Divya Putrajeevak Seed' and seeking a response from the government. Health Minister J.P. Nadda assured that the government "will look into it and action will be taken".

The website of Ramdev's Divya Pharmacy prices the product at $10.99 and the description says it is a "unique herbal product of putrajeevak which is aphrodisiac, controls habitual abortion and helps in (curing) sterility".

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 01 2015 | 8:16 PM IST

Next Story